Proxy Votes Now

Home › Activist investors › Rubric Capital

Rubric Capital

Other large holder. Positions and campaigns from Rubric Capital’s SEC filings. Updated November 20, 2026.

Filer entities
Rubric Capital Management LP; Rubric Capital Management, LLC
SEC CIKs
1687509 (Rubric Capital Management LP); 1628676 (Rubric Capital Management, LLC)
SEC filings
Schedule 13D filings · 13F reports · soliciting material
Latest 13F
Quarter ended Sep 30, 2026, filed Nov 16, 2026: 86 US-listed positions reported; 55 of 1% or more of a company without a 13D are listed below.
59current positions
40new or changed in 90 days; 5 exited
0active campaigns
3campaigns on record

Active campaigns

No active campaign by this definition (see How to read this).

Current positions (59)

CompanyStakeSourceFirst disclosedLast changeSince previous filingFlagsStated intent
Integra Lifesciences Holdings Corp. 9.45%7,353,934 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 22, 2026 Nov 13, 2024 Decreased Nov 16, 2026 ▼ 0.52 pts Decreased 13F: none stated
Enovis Corporation 9.19%5,300,000 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 30, 2026 May 10, 2019 Increased Nov 16, 2026 ▲ 2.42 pts Increased 13F: none stated
MannKind Corporation 9.15%29,430,000 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 23, 2026 Nov 14, 2025 Increased Nov 16, 2026 ▲ 3.55 pts Increased 13F: none stated
MeiraGTx Holdings Plc 8.77%8,427,279 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 11, 2026 May 14, 2025 Decreased Nov 16, 2026 ▼ 0.70 pts Decreased 13F: none stated
Liberty Latin America LTD. 8.76%17,548,084 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Mar 31, 2026 Nov 14, 2025 Decreased Nov 16, 2026 ▼ 0.94 pts Decreased 13F: none stated
Cimpress PLC 8.43%2,075,000 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 26, 2026 Feb 10, 2023 Increased Nov 16, 2026 ▲ 1.24 pts Increased 13F: none stated
Ecovyst Inc. 8.02%8,711,888 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 30, 2026 Aug 14, 2025 Increased Nov 16, 2026 ▲ 0.52 pts Increased 13F: none stated
Liberty Global PLC 7.31%24,480,483 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Mar 31, 2026 Feb 13, 2024 Increased Nov 16, 2026 ▲ 1.04 pts Increased 13F: none stated
Edesa Biotech, Inc. 7.00%622,200 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of May 13, 2026 May 14, 2025 Decreased Nov 16, 2026 ▼ 0.53 pts Decreased 13F: none stated
Abeona Therapeutics Inc. 5.84%3,339,707 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 10, 2026 Aug 14, 2026 Increased Nov 16, 2026 ▲ 4.78 pts Increased 13F: none stated
Six Flags Entertainment Corporation 5.81%5,944,841 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 30, 2026 Nov 16, 2026 — — New 13F: none stated
ADMA Biologics, Inc. 5.57%12,352,584 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 30, 2026 May 15, 2026 Increased Nov 16, 2026 ▲ 1.40 pts Increased 13F: none stated
Ardelyx, Inc. 5.53%13,908,138 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 27, 2026 Nov 15, 2023 Decreased Nov 16, 2026 ▼ 0.97 pts Decreased 13F: none stated
CoreCivic, Inc. 4.66%4,030,385 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 30, 2026 May 14, 2025 Increased Nov 16, 2026 ▲ 1.78 pts Increased 13F: none stated
PennyMac Financial Services, Inc. 4.62%2,400,000 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 30, 2026 Aug 10, 2020 Increased Nov 16, 2026 ▲ 1.35 pts Increased 13F: none stated
QuidelOrtho Corporation 4.57%3,133,148 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 28, 2026 Nov 15, 2023 Decreased Nov 16, 2026 ▼ 0.25 pts Decreased 13F: none stated
Nurix Therapeutics, Inc. 4.55%4,966,827 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Sep 30, 2026 Feb 13, 2026 Decreased Nov 16, 2026 ▼ 2.42 pts Decreased 13F: none stated
Ftai Aviation LTD. 4.11%4,200,000 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 30, 2026 May 14, 2025 Increased Nov 16, 2026 ▲ 1.19 pts Increased 13F: none stated
The GEO Group, Inc. 3.92%5,187,353 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 3, 2026 May 14, 2025 Increased Nov 16, 2026 ▲ 0.78 pts Increased 13F: none stated
Newell Brands Inc. 3.87%16,500,000 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 26, 2026 Nov 14, 2025 Increased Nov 16, 2026 ▲ 0.12 pts Increased 13F: none stated
Indivior Pharmaceuticals, Inc. 3.27%3,862,989 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 9, 2026 Nov 16, 2026 — — New 13F: none stated
Biohaven LTD. 3.23%4,875,000 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 26, 2026 Aug 14, 2026 Increased Nov 16, 2026 ▲ 2.09 pts Increased 13F: none stated
Viatris Inc. 3.14%36,000,000 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 2, 2026 Aug 11, 2023 Increased Nov 16, 2026 ▲ 0.17 pts Increased 13F: none stated
Supernus Pharmaceuticals, Inc. 2.99%1,739,892 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 27, 2026 Nov 16, 2026 — — New 13F: none stated
Matthews International Corporation 2.82%878,734 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Jun 30, 2026 Nov 16, 2026 — — New 13F: none stated
Schrodinger, Inc. 2.68%1,980,830 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Mar 31, 2026 May 13, 2022 Decreased Nov 16, 2026 ▼ 5.97 pts Decreased 13F: none stated
Amneal Pharmaceuticals, Inc. 2.67%8,536,755 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Jul 31, 2026 Aug 11, 2023 Decreased Nov 16, 2026 ▼ 0.51 pts Decreased 13F: none stated
Core Scientific, Inc. 2.17%7,000,000 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 2, 2026 Nov 16, 2026 — — New 13F: none stated
Driven Brands Holdings Inc. 2.14%3,528,045 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 4, 2026 May 15, 2026 Decreased Nov 16, 2026 ▼ 1.07 pts Decreased 13F: none stated
Collegium Pharmaceutical, Inc. 2.01%625,819 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 31, 2026 May 14, 2020 Decreased Nov 16, 2026 ▼ 1.92 pts Decreased 13F: none stated
Vistance Networks, Inc. 1.96%4,000,000 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 22, 2026 May 15, 2026 Increased Nov 16, 2026 ▲ 1.10 pts Increased 13F: none stated
Fluor Corporation 1.93%2,469,762 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 30, 2026 Feb 14, 2022 Decreased Nov 16, 2026 ▼ 1.82 pts Decreased 13F: none stated
Service Properties Trust 1.79%2,322,880 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 2, 2026 Aug 14, 2026 Increased Nov 16, 2026 ▲ 1.09 pts Increased 13F: none stated
StubHub Holdings, Inc. 1.73%6,213,747 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Mar 31, 2026 Feb 13, 2026 Increased Nov 16, 2026 ▲ 0.34 pts Increased 13F: none stated
Arbutus Biopharma Corporation 1.69%3,343,932 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 10, 2026 Feb 10, 2023 Decreased Nov 16, 2026 ▼ 2.12 pts Decreased 13F: none stated
The Andersons, Inc. 1.42%477,826 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 2, 2026 Feb 13, 2026 Decreased Nov 16, 2026 ▼ 1.52 pts Decreased 13F: none stated
Aptiv PLC 1.31%2,651,364 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 30, 2026 Nov 16, 2026 — — New 13F: none stated
Establishment Labs Holdings Inc. 1.24%370,098 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 5, 2026 Aug 14, 2026 Decreased Nov 16, 2026 ▼ 1.07 pts Decreased 13F: none stated
Sonoco Products Company 1.21%1,192,329 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 16, 2026 Aug 14, 2026 Increased Nov 16, 2026 ▲ 0.05 pts Increased 13F: none stated
Roivant Sciences Ltd. 1.04%7,481,524 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Jul 31, 2026 Feb 10, 2023 Increased Nov 16, 2026 ▲ 0.21 pts Increased 13F: none stated
Heron Therapeutics, Inc. /De/ 15.9%30,046,828 shares Schedule 13D/A, filed Oct 17, 2025 Jul 25, 2023 Increased Oct 17, 2025 ▼ 1.60 pts — Standard Item 4 language
Zymeworks Inc. 9.86%7,000,000 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 4, 2026 Feb 10, 2023 — 0.00 pts — 13F: none stated
Prothena Corporation plc 9.74%5,000,000 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 29, 2026 Nov 14, 2025 — 0.00 pts — 13F: none stated
Xperi Inc. 9.2%4,143,744 shares Schedule 13D/A, filed Jun 11, 2024 Jan 23, 2024 — — — Standard Item 4 language
Orthofix Medical Inc. 9.14%3,721,715 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Jul 31, 2026 May 12, 2023 — 0.00 pts — 13F: none stated
ARS Pharmaceuticals, Inc. 8.50%8,540,861 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 3, 2026 Aug 15, 2022 — ▼ 0.09 pts — 13F: none stated
Talen Energy Corporation 8.28%3,602,171 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 3, 2026 Nov 13, 2024 — ▲ 0.76 pts — 13F: none stated
Edgewell Personal Care Company 7.60%3,504,525 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Jul 31, 2026 Feb 13, 2026 — ▼ 0.09 pts — 13F: none stated
Mativ Holdings, Inc. 7.25%4,000,000 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 2, 2026 Nov 14, 2022 — ▲ 0.03 pts — 13F: none stated
Arcutis Biotherapeutics, Inc. 6.66%8,421,577 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 30, 2026 Aug 15, 2022 — ▲ 0.08 pts — 13F: none stated
OPKO Health, Inc. 6.44%47,791,243 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 20, 2026 May 10, 2024 — ▲ 0.03 pts — 13F: none stated
Delek US Holdings, Inc. 4.43%2,687,449 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 30, 2026 Nov 13, 2024 — ▲ 0.04 pts — 13F: none stated
Seaport Entertainment Group Inc. 4.43%568,530 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 3, 2026 Nov 13, 2024 — ▼ 0.01 pts — 13F: none stated
Target Hospitality Corp. 2.60%2,586,389 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 6, 2026 May 10, 2019 — 0.00 pts — 13F: none stated
Dnow Inc. 2.16%3,898,635 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 29, 2026 May 15, 2026 — ▲ 0.01 pts — 13F: none stated
Hudson Pacific Properties Inc. 1.88%1,019,598 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of May 1, 2026 Aug 14, 2026 — 0.00 pts — 13F: none stated
Compass, Inc. 1.07%8,218,394 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 3, 2026 Feb 13, 2026 — ▼ 0.01 pts — 13F: none stated
Mereo BioPharma Group plc — Schedule 13D/A, filed Jun 17, 2024stake not read from this filing’s format: see the filing Jun 16, 2023 — — — Standard Item 4 language
TherapeuticsMD, Inc. — Schedule 13D/A, filed Nov 17, 2023stake not read from this filing’s format: see the filing Jun 30, 2023 — — — Standard Item 4 language

Stake: the latest 13D’s percent of the class (the largest single reporting person’s, as filed), or for a 13F the reported shares as a percent of the company’s shares outstanding on the date shown. Since previous filing: the change in percentage points against the investor’s previous 13D on the company, or its previous 13F.

Stated intent (13D Item 4)

Item 4 of a Schedule 13D (“Purpose of Transaction”) is where the investor states its plans. The label is a plain reading of that text; the excerpt is quoted from the filing.

Heron Therapeutics, Inc. /De/ · Standard Item 4 language

“On October 15, 2025, the Issuer filed a Current Report on Form 8-K with the SEC disclosing that it obtained Stockholder Approval, as a result of which, the 94,610 shares of Preferred Stock beneficially owned by the Reporting Persons automatically converted, without any action on the part of the holders thereof, into 946,100 Shares. Additionally, as previously disclosed, on August 8, 2025, a certain…”

Item 4 in the Schedule 13D/A filed Oct 17, 2025.

Xperi Inc. · Standard Item 4 language

“Item 4 is hereby amended to add the following: The Reporting Persons are deeply concerned by the Issuer’s continued poor stock performance. The Reporting Persons intend to continue monitoring the Issuer’s performance and will not hesitate to take any action that they believe is necessary to protect the best interests of stockholders.”

Item 4 in the Schedule 13D/A filed Jun 11, 2024.

Mereo BioPharma Group plc · Standard Item 4 language

“Item 4 of the Schedule 13D is hereby amended by adding the following. On June 14, 2024, the Issuer filed a Form 8-K dated June 14, 2024 (the “Form 8-K”), and a Form 424B5 dated June 14, 2024, with the Securities and Exchange Commission in connection with an underwritten offering of 12,531,300 ADSs (such Form 424B5, “Form 424B5,” and such offering, the “Offering”) by the Issuer. The Reporting Persons…”

Item 4 in the Schedule 13D/A filed Jun 17, 2024.

TherapeuticsMD, Inc. · Standard Item 4 language

“Item 4 of the Schedule 13D is hereby amended by adding the following: As disclosed in the Current Report on Form 8-K filed by the Issuer with the SEC on May 5, 2023, the Issuer and Rubric Capital entered into a Subscription Agreement on May 1, 2023 (the “ Subscription Agreement ”) p ursuant to which the Issuer agreed to sell to Rubric Capital, or one or more of its affiliates, up to an aggregate of…”

Item 4 in the Schedule 13D/A filed Nov 17, 2023.

Campaigns are compiled from SEC filings (13D, proxy contest filings and settlement 8-Ks); campaigns run without SEC filings, e.g. by public letter below the 5% threshold, may not appear.

Past campaigns (3)
CompanyOutcome or last statusDateFirst filingHighest stageFilingsMeeting / votes
Heron Therapeutics, Inc. /De/ Settled (agreement with the company) Feb 22, 2023 Feb 6, 2023 — latest (5) —
Xperi Inc.Board seats Contested vote held — 0 of 2 of the activist's nominees elected May 24, 2024 Jan 23, 2024 Proxy contest filed latest (13) how managers voted
Mereo BioPharma Group plc Settled (agreement with the company) Apr 15, 2024 May 26, 2022 — latest (2) —
Past positions (5)
CompanyLast stakeSourceOutcomeDate
ANI Pharmaceuticals, Inc. 1.15% 13F, quarter ended Jun 30, 2026filed Aug 14, 2026; % of shares outstanding as of Dec 31, 2025 Not in the latest 13F Nov 16, 2026
Mercury General Corporation 2.78% 13F, quarter ended Jun 30, 2026filed Aug 14, 2026; % of shares outstanding as of Jul 30, 2026 Not in the latest 13F Nov 16, 2026
Teva Pharmaceutical Industries LTD. 1.34% 13F, quarter ended Jun 30, 2026filed Aug 14, 2026; % of shares outstanding as of Jun 30, 2026 Not in the latest 13F Nov 16, 2026
Trevi Therapeutics, Inc. 1.76% 13F, quarter ended Jun 30, 2026filed Aug 14, 2026; % of shares outstanding as of Jul 31, 2026 Not in the latest 13F Nov 16, 2026
Tripadvisor, Inc. 2.08% 13F, quarter ended Jun 30, 2026filed Aug 14, 2026; % of shares outstanding as of Jun 30, 2026 Not in the latest 13F Nov 16, 2026

How large managers voted in Rubric Capital’s proxy contests (meetings since July 2023)

Fund votes come from Form N-PX filings, which this site holds from July 1, 2023 (meetings through June 30, 2026; later meetings appear when the managers file their next N-PX); earlier contests and campaigns that settled before a vote are listed under the activist’s campaigns.

Contested director elections at which Rubric Capital had nominees on the ballot, from the managers’ N-PX vote reports and the company’s Form 8-K (Item 5.07) results. A manager “backed” a side when most of its funds’ votes on that side’s nominees were FOR; with a universal proxy card a fund can vote for nominees of both sides, so the counts are shown too.

Top 20 managers across 1 contest

ManagerBacked the activistXperi Inc.
2024
BlackRock0 of 1 (0%) Company
Vanguard0 of 1 (0%) Company
John Hancock0 of 1 (0%) Company
Dimensional0 of 1 (0%) Company
JPMorgan1 of 1 (100%) Activist
Fidelity0 of 1 (0%) Company
State Street0 of 1 (0%) Company
ADVISORS SERIES TRUST1 of 1 (100%) Activist
Charles Schwab0 of 1 (0%) Company
Hartford1 of 1 (100%) Activist
New York Life1 of 1 (100%) Activist
Invesco0 of 1 (0%) Company
Columbia Threadneedle0 of 1 (0%) Company
MoA Funds Corp0 of 1 (0%) Company
TIAA0 of 1 (0%) Company
Prudential/PGIM0 of 1 (0%) Company
Brighthouse0 of 1 (0%) Company
Equitable0 of 1 (0%) Company
Nationwide0 of 1 (0%) Company
Jackson National0 of 1 (0%) Company

— = no N-PX votes on the contested director elections found for that manager.

Xperi Inc. · meeting May 24, 2024 · 0 of 2 of the activist’s nominees elected

Result: Form 8-K, Item 5.07. Activist’s nominees: Deborah S. Conrad (not elected (8-k tally)); Thomas A. Lacey (not elected (8-k tally)). Company’s nominees: Darcy Antonellis (elected (8-k tally)); Laura J. Durr (elected); David C. Habiger (elected); Jon E. Kirchner (elected); Christopher Seams (elected).

ManagerStanceFOR the activist’s nomineesAvg. shares FOR each activist nomineeFOR the company’s nominees
BlackRock Backed the company's nominees 0 of 26 fund votes 0 65 of 65 fund votes
Vanguard Backed the company's nominees 0 of 30 fund votes 0 75 of 75 fund votes
John Hancock Backed the company's nominees 0 of 10 fund votes 0 25 of 25 fund votes
Dimensional Backed the company's nominees 0 of 34 fund votes 0 85 of 85 fund votes
JPMorgan Backed the activist's nominees 10 of 10 fund votes 666,424 15 of 25 fund votes
Fidelity Backed the company's nominees 0 of 28 fund votes 0 70 of 70 fund votes
State Street Backed the company's nominees 0 of 20 fund votes 0 50 of 50 fund votes
ADVISORS SERIES TRUST Backed the activist's nominees 2 of 2 fund votes 285,661 3 of 5 fund votes
Charles Schwab Backed the company's nominees 0 of 10 fund votes 0 25 of 25 fund votes
Hartford Backed the activist's nominees 2 of 2 fund votes 170,814 3 of 5 fund votes
New York Life Backed the activist's nominees 2 of 2 fund votes 165,907 3 of 5 fund votes
Invesco Backed the company's nominees 0 of 8 fund votes 0 20 of 20 fund votes
Columbia Threadneedle Backed the company's nominees 0 of 4 fund votes 0 10 of 10 fund votes
MoA Funds Corp Backed the company's nominees 0 of 6 fund votes 0 15 of 15 fund votes
TIAA Backed the company's nominees 0 of 12 fund votes 0 30 of 30 fund votes
Prudential/PGIM Backed the company's nominees 2 of 6 fund votes 50,197 13 of 15 fund votes
Brighthouse Backed the company's nominees 2 of 10 fund votes 63,043 23 of 25 fund votes
Equitable Backed the company's nominees 0 of 14 fund votes 0 35 of 35 fund votes
Nationwide Backed the company's nominees 0 of 12 fund votes 0 25 of 30 fund votes
Jackson National Backed the company's nominees 0 of 6 fund votes 0 15 of 15 fund votes
AIG/SunAmerica Backed the company's nominees 0 of 6 fund votes 0 15 of 15 fund votes
Voya Backed the company's nominees 0 of 8 fund votes 0 20 of 20 fund votes
Lincoln Financial Backed the company's nominees 2 of 8 fund votes 24,748 18 of 20 fund votes
WisdomTree Backed the company's nominees 0 of 2 fund votes 0 5 of 5 fund votes
BNY Mellon Backed the company's nominees 0 of 6 fund votes 0 15 of 15 fund votes
QUANTITATIVE MASTER SERIES LLC Backed the company's nominees 0 of 2 fund votes 0 5 of 5 fund votes
American Century Backed the company's nominees 0 of 8 fund votes 0 20 of 20 fund votes
Principal Backed the company's nominees 2 of 6 fund votes 4,946 13 of 15 fund votes
Nushares ETF Trust Backed the company's nominees 0 of 2 fund votes 0 5 of 5 fund votes
Russell Investments Backed the company's nominees 0 of 8 fund votes 0 20 of 20 fund votes
DWS Backed the company's nominees 0 of 6 fund votes 0 15 of 15 fund votes
Thrivent Backed the company's nominees 0 of 2 fund votes 0 5 of 5 fund votes
GuideStone Backed the company's nominees 0 of 2 fund votes 0 5 of 5 fund votes
Allianz Backed the company's nominees 0 of 6 fund votes 0 15 of 15 fund votes
PFM Multi-Manager Series Trust Backed the company's nominees 0 of 2 fund votes 0 5 of 5 fund votes
Direxion Shares ETF Trust Backed the company's nominees 0 of 2 fund votes 0 5 of 5 fund votes
Empower Backed the company's nominees 0 of 2 fund votes 0 4 of 5 fund votes
Catholic Responsible Investments Funds Backed the company's nominees 0 of 2 fund votes 0 5 of 5 fund votes
Northern Trust Backed the company's nominees 0 of 4 fund votes 0 8 of 10 fund votes
T. Rowe Price Backed the company's nominees 0 of 4 fund votes 0 10 of 10 fund votes

31 smaller managers not shown.

Source: N-PX reports filed by 71 managers for the meeting of May 24, 2024; a nominee’s side is read from how most filers labelled the ballot item (two or more filers, 70% agreeing).

Track record

How each campaign on record ended, as read from the filings: settlements disclosed in the company’s 8-K or the investor’s 13D, contested votes (8-K Item 5.07), withdrawals and 13D amendments below 5%.

2Settlement
1Contest vote: nominees not elected
Outcome of each campaign (3)
CompanyOutcomeDetailDateFirst filing
Heron Therapeutics, Inc. /De/ Settlement agreement with the company Aug 12, 2025 Feb 6, 2023
Xperi Inc. Contest vote: nominees not elected 0 of 2 of the activist's nominees elected May 24, 2024 Jan 23, 2024
Mereo BioPharma Group plc Settlement agreement with the company Apr 15, 2024 May 26, 2022

Share price after the first 13D

The change in the company’s closing share price from the first trading day on or before the investor’s first Schedule 13D to the latest close, and to 6 and 12 months after it, beside the S&P 500 (SPY) over the same dates. This is a price change after a filing date: it is not attributed to the investor, and it is not the investor’s return. Coverage: 0 of 4 13D positions have prices (the site’s daily price history starts November 10, 2025, and covers only listed tickers it tracks).

Settlement terms

Terms of the cooperation agreements, read by rules from the company’s Form 8-K (or the investor’s 13D where it describes the agreement). Each term is quoted from the filing; terms a rule did not find are not listed, so a missing term is not evidence that the agreement lacks it.

Heron Therapeutics, Inc. /De/ · Jul 24, 2023 · Ownership cap, Directors named, Committee role

Other disclosed holders around the same time

Filings by other activists on this list (their first 13D or 13F on the company) and by other holders of 5% or more (Schedule 13D or 13G) dated within 180 days of Rubric Capital’s first disclosure in the same company. They are listed together by date only; nothing here says the holders act together.

Core Scientific, Inc. · Rubric Capital first disclosed Nov 16, 2026 · 6 other filings
HolderFormDateStake
Jane Street Group, LLC Schedule 13G May 26, 2026 7.5%
Vanguard Capital Management Schedule 13G Jul 31, 2026 5.1%
Kenneth Griffin Schedule 13G Aug 5, 2026 6.5%
Jericho Capital Asset Management L.P. Schedule 13G Aug 14, 2026 7.2%
Pentwater Capital Management LP Schedule 13G Aug 14, 2026 0.4%
Valiant Capital Management, L.P. Schedule 13G Aug 14, 2026 5.3%
Six Flags Entertainment Corporation · Rubric Capital first disclosed Nov 16, 2026 · 3 other filings
HolderFormDateStake
BlackRock, Inc. Schedule 13G Jul 30, 2026 14.4%
Darlington Partners Capital Management, LP Schedule 13G Aug 14, 2026 7.5%
H Partners Management, LLC Schedule 13D Nov 16, 2026 7.2%
Matthews International Corporation · Rubric Capital first disclosed Nov 16, 2026 · 3 other filings
HolderFormDateStake
Vanguard Capital Management Schedule 13G Jul 31, 2026 5.0%
Vanguard Portfolio Management Schedule 13G Jul 31, 2026 4.0%
Oaktree Capital Management LP Schedule 13G Aug 10, 2026 6.2%
Supernus Pharmaceuticals, Inc. · Rubric Capital first disclosed Nov 16, 2026 · 1 other filing
HolderFormDateStake
Millennium Management LLC Schedule 13G Aug 6, 2026 6.6%
Aptiv PLC · Rubric Capital first disclosed Nov 16, 2026 · 1 other filing
HolderFormDateStake
Barrow Hanley Mewhinney & Strauss LLC Schedule 13G Aug 12, 2026 5.1%
Establishment Labs Holdings Inc. · Rubric Capital first disclosed Aug 14, 2026 · 4 other filings
HolderFormDateStake
Juan Jose Chacon Quiros Schedule 13G Feb 19, 2026 4.9%
Brown Advisory Inc Schedule 13G May 15, 2026 5.4%
BlackRock, Inc. Schedule 13G Jul 28, 2026 5.4%
JW Asset Management, LLC Schedule 13G Jul 31, 2026 9.2%
Abeona Therapeutics Inc. · Rubric Capital first disclosed Aug 14, 2026 · 7 other filings
HolderFormDateStake
Daniel Kaufman Schedule 13G Mar 27, 2026 5.2%
Funicular Funds, LP Schedule 13G Apr 6, 2026 5.3%
AIGH Capital Management LLC Schedule 13G Apr 28, 2026 5.4%
Nantahala Capital Partners Limited Partnership Schedule 13G May 15, 2026 5.8%
Nantahala Capital Management, LLC Schedule 13G May 15, 2026 10.0%
Montanova Capital, LLC Schedule 13G Aug 14, 2026 0.9%
James Russell Revocable Trust Schedule 13D Oct 23, 2026 6.1%
Service Properties Trust · Rubric Capital first disclosed Aug 14, 2026 · 6 other filings
HolderFormDateStake
Helix Partners Management LP Schedule 13G Apr 7, 2026 8.6%
FF Hybrid, LP Schedule 13G Apr 8, 2026 9.4%
The RMR Group LLC Schedule 13D Apr 9, 2026 6.8%
Charles Schwab Investment Management Inc Schedule 13G May 14, 2026 4.7%
Vanguard Portfolio Management Schedule 13G Jul 31, 2026 5.1%
Capital World Investors Schedule 13G Aug 12, 2026 5.4%
Hudson Pacific Properties Inc. · Rubric Capital first disclosed Aug 14, 2026 · 5 other filings
HolderFormDateStake
Vanguard Portfolio Management Schedule 13G Apr 29, 2026 5.3%
Vanguard Capital Management Schedule 13G Apr 30, 2026 5.1%
Philosophy Capital Management LLC Schedule 13G May 15, 2026 6.8%
T. Rowe Price Investment Management, Inc. Schedule 13G May 15, 2026 5.2%
Cohen & Steers, Inc. Schedule 13G Aug 14, 2026 18.2%
Biohaven LTD. · Rubric Capital first disclosed Aug 14, 2026 · 3 other filings
HolderFormDateStake
Janus Henderson Group PLC Schedule 13G May 15, 2026 11.7%
JANUS HENDERSON GROUP Ltd. Schedule 13G Jul 8, 2026 5.7%
Woodline Partners LP Schedule 13G Aug 14, 2026 5.1%
Dnow Inc. · Rubric Capital first disclosed May 15, 2026 · 6 other filings
HolderFormDateStake
The Vanguard Group Schedule 13G Jan 30, 2026 10.5%
Wellington Management Group LLP Schedule 13G Feb 10, 2026 5.8%
Vanguard Capital Management Schedule 13G Apr 29, 2026 5.2%
Vanguard Portfolio Management Schedule 13G Apr 29, 2026 5.6%
Engine Capital 13F May 15, 2026 2.9%
Dimensional Fund Advisors LP Schedule 13G Jul 14, 2026 4.4%
ADMA Biologics, Inc. · Rubric Capital first disclosed May 15, 2026 · 4 other filings
HolderFormDateStake
Invesco Ltd. Schedule 13G Feb 12, 2026 5.0%
Vanguard Capital Management Schedule 13G Apr 29, 2026 5.1%
State Street Corporation Schedule 13G Aug 7, 2026 7.4%
Nantahala Capital 13F Aug 14, 2026 1.2%
Vistance Networks, Inc. · Rubric Capital first disclosed May 15, 2026 · 2 other filings
HolderFormDateStake
Mangrove Partners 13F Feb 17, 2026 4.6%
Vanguard Capital Management Schedule 13G Jul 31, 2026 5.0%
Driven Brands Holdings Inc. · Rubric Capital first disclosed May 15, 2026 · 1 other filing
HolderFormDateStake
FMR LLC Schedule 13G May 6, 2026 5.0%
Compass, Inc. · Rubric Capital first disclosed Feb 13, 2026 · 6 other filings
HolderFormDateStake
Quad-C Partners IX, L.P. Schedule 13G Aug 29, 2025 5.1%
FMR LLC Schedule 13G Nov 5, 2025 12.7%
SB Investment Advisers (UK) Limited Schedule 13G Feb 17, 2026 4.5%
Vanguard Portfolio Management Schedule 13G Apr 29, 2026 8.2%
BlackRock, Inc. Schedule 13G Jul 27, 2026 7.0%
Vanguard Capital Management Schedule 13G Jul 31, 2026 5.0%
Edgewell Personal Care Company · Rubric Capital first disclosed Feb 13, 2026 · 5 other filings
HolderFormDateStake
Brandes Investment Partners, LP Schedule 13G Sep 5, 2025 10.9%
American Century Investment Management, Inc. Schedule 13G Nov 14, 2025 8.5%
Dimensional Fund Advisors LP Schedule 13G Jan 21, 2026 5.6%
Vanguard Capital Management Schedule 13G Apr 29, 2026 5.1%
Vanguard Portfolio Management Schedule 13G Apr 29, 2026 6.6%
The Andersons, Inc. · Rubric Capital first disclosed Feb 13, 2026 · 3 other filings
HolderFormDateStake
First Trust Portfolios L.P. Schedule 13G Oct 31, 2025 0.5%
Vanguard Portfolio Management Schedule 13G Apr 28, 2026 7.1%
Vanguard Capital Management Schedule 13G Jul 31, 2026 5.0%
Nurix Therapeutics, Inc. · Rubric Capital first disclosed Feb 13, 2026 · 7 other filings
HolderFormDateStake
FMR LLC Schedule 13G Nov 5, 2025 11.5%
Commodore Capital LP Schedule 13G Nov 14, 2025 4.9%
Baker Bros. Advisors LP Schedule 13G Feb 17, 2026 7.2%
Redmile Group, LLC Schedule 13G Apr 24, 2026 9.9%
Vestal Point Capital, LP Schedule 13G May 15, 2026 6.3%
Deep Track Capital, LP Schedule 13G May 15, 2026 6.2%
Vanguard Capital Management Schedule 13G Jul 31, 2026 5.0%
StubHub Holdings, Inc. · Rubric Capital first disclosed Feb 13, 2026 · 3 other filings
HolderFormDateStake
PointState Capital LP Schedule 13G Jan 9, 2026 7.2%
WestCap Management, LLC Schedule 13G Jan 21, 2026 11.6%
Deer VIII & Co. L.P. Schedule 13G Apr 29, 2026 6.1%
Prothena Corporation plc · Rubric Capital first disclosed Nov 14, 2025 · 7 other filings
HolderFormDateStake
Logos Global Management LP Schedule 13G Jun 4, 2025 5.5%
Wellington Management Group LLP Schedule 13G Jun 5, 2025 0.2%
Scully William P Schedule 13G Aug 13, 2025 9.9%
Fennell Todd W. Schedule 13G Aug 13, 2025 8.1%
ADAR1 Capital Management, LLC Schedule 13G Aug 14, 2025 6.3%
T. Rowe Price Associates, Inc. Schedule 13G Aug 14, 2025 0.1%
BlackRock, Inc. Schedule 13G Oct 17, 2025 5.7%
Newell Brands Inc. · Rubric Capital first disclosed Nov 14, 2025 · 7 other filings
HolderFormDateStake
Dimensional Fund Advisors LP Schedule 13G Jul 15, 2025 5.0%
Massachusetts Financial Services Company Schedule 13G Aug 4, 2025 4.9%
Cooper Creek Partners Management LLC Schedule 13G Aug 13, 2025 6.2%
AQR Capital Management, LLC Schedule 13G Feb 13, 2026 5.0%
BlackRock, Inc. Schedule 13G Apr 24, 2026 11.4%
Vanguard Portfolio Management Schedule 13G Apr 29, 2026 5.5%
Vanguard Capital Management Schedule 13G Apr 30, 2026 5.2%
MannKind Corporation · Rubric Capital first disclosed Nov 14, 2025 · 1 other filing
HolderFormDateStake
State Street Corporation Schedule 13G May 12, 2026 6.1%
Ecovyst Inc. · Rubric Capital first disclosed Aug 14, 2025 · 1 other filing
HolderFormDateStake
Hotchkis and Wiley Capital Management, LLC Schedule 13G Aug 13, 2025 9.6%
Ftai Aviation LTD. · Rubric Capital first disclosed May 14, 2025 · 5 other filings
HolderFormDateStake
Capital International Investors Schedule 13G Jan 3, 2025 10.6%
Shikiar Asset Management Inc Schedule 13G Feb 5, 2025 6.3%
BlackRock, Inc. Schedule 13G Feb 5, 2025 9.4%
Washington State Investment Board Schedule 13G Feb 14, 2025 2.1%
Capital World Investors Schedule 13G Aug 13, 2025 5.4%
CoreCivic, Inc. · Rubric Capital first disclosed May 14, 2025 · 2 other filings
HolderFormDateStake
Cooper Creek Partners Management LLC Schedule 13G Feb 14, 2025 5.6%
BlackRock, Inc. Schedule 13G Apr 28, 2025 14.9%
The GEO Group, Inc. · Rubric Capital first disclosed May 14, 2025 · 2 other filings
HolderFormDateStake
Wolf Hill Capital Management, LP Schedule 13G Feb 14, 2025 5.7%
FMR LLC Schedule 13G Aug 6, 2025 2.0%
Edesa Biotech, Inc. · Rubric Capital first disclosed May 14, 2025 · 1 other filing
HolderFormDateStake
Velan Capital Master Fund LP Schedule 13D Feb 18, 2025 10.0%
Mercury General Corporation · Rubric Capital first disclosed May 14, 2025 · 1 other filing
HolderFormDateStake
BlackRock, Inc. Schedule 13G Apr 17, 2025 7.3%
Seaport Entertainment Group Inc. · Rubric Capital first disclosed Nov 13, 2024 · 1 other filing
HolderFormDateStake
Pershing Square Schedule 13D Aug 7, 2024 40.1%
Talen Energy Corporation · Rubric Capital first disclosed Nov 13, 2024 · 4 other filings
HolderFormDateStake
Two Seas Capital LP 13F Aug 14, 2024 1.2%
Sachem Head 13F Nov 14, 2024 2.7%
Carronade Capital 13F Nov 14, 2024 1.5%
The Vanguard Group Schedule 13G Jan 8, 2025 10.4%
Delek US Holdings, Inc. · Rubric Capital first disclosed Nov 13, 2024 · 1 other filing
HolderFormDateStake
BlackRock, Inc. Schedule 13G Apr 23, 2025 7.9%
Integra Lifesciences Holdings Corp. · Rubric Capital first disclosed Nov 13, 2024 · 1 other filing
HolderFormDateStake
Invesco Ltd. Schedule 13G May 9, 2025 5.3%
Orthofix Medical Inc. · Rubric Capital first disclosed May 12, 2023 · 1 other filing
HolderFormDateStake
Engine Capital, L.P. Schedule 13D Nov 3, 2023 —

How to read this

Flags (last 90 days)
New first disclosed in the last 90 days. Increased / Decreased shares up or down in a 13D/A or 13F filed in that time. Below 5% a 13D/A reported less than 5%, the reporting threshold. Exited a 13D/A reported no shares, or the investor’s 13F no longer lists a company it listed before.
Active campaign
A contested meeting at which the investor is soliciting proxies is still to be held; or in the last 12 months it filed a proxy-contest document (PREC14A, DEFC14A or DFAN14A soliciting material), stated in a 13D that it nominated directors, filed a letter or presentation to the board or shareholders, or stated public demands in a 13D — and no settlement, withdrawal, contested vote or 13D below 5% is dated on or after the latest such filing. Status is the furthest step since then: Public demands in a 13D < Public letter or soliciting material < Nominations made < Proxy contest filed.
Sources and limits
SEC EDGAR only. 13D data covers filings since June 2023; 13F reports are quarterly and filed up to 45 days after the quarter, and do not show swaps, most options or non-US holdings. Settlements are cooperation agreements disclosed in the company’s 8-K or stated in the investor’s 13D; board seats are read from the 8-K. Text marked Summary of the filing is checked against the filing, whose words are quoted beside it. Nothing on this page predicts what the investor will do.